In detail, von Essen et al. reported a significantly increased expression of chemokine receptors (CCR2, CCR5, CCR6, CXCR3) and adhesion molecules such as CD49d and MCAM-1 (significant in the CD4+ population only) in the CD20+ compared to the CD20− compartment of T cells isolated from the peripheral blood of RR-MS patients; interestingly, no differences in the expression of such molecules were found in CD20+ T cells from MS and HD, suggesting that higher CNS migration potential in T cells is deeply associated with the expression of the CD20 marker [13]. Here, CD4 is linked to myeloid sarcoma.